Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide

被引:20
作者
Frean, J
Klugman, KP [1 ]
Arntzen, L
Bukofzer, S
机构
[1] Univ Witwatersrand, MRC, NHLS Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa
[2] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa
[3] Emory Univ, Dept Int Hlth, Atlanta, GA 30322 USA
[4] Abbott Labs, Chicago, IL USA
关键词
anthrax; antibiotics; fluoroquinolones; macrolides; ketolides;
D O I
10.1093/jac/dkg364
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To determine the susceptibility of southern African strains of Bacillus anthracis to new, investigational agents as well as conventional antibiotics. Materials and methods: The MICs of 26 isolates of B. anthracis from South Africa and Zimbabwe, as well as the Sterne vaccine strain and a type culture strain, were determined by agar dilution. Results: The most active antimicrobial agents were the novel ketolide ABT 773, new and conventional fluoroquinolones, and doxycycline; macrolides were intermediately active. The lack of activity of extended-spectrum cephalosporins against B. anthracis was confirmed. Conclusions: Susceptibility to conventional antibiotics was in keeping with previous studies. Two new fluoroquinolones and a ketolide showed promising in vitro activity that would support their further evaluation in animal models of anthrax.
引用
收藏
页码:297 / 299
页数:3
相关论文
共 10 条
[1]  
Anonymous, 2001, MMWR Morb Mortal Wkly Rep, V50, P909
[2]   In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones [J].
Brook, I ;
Elliott, TB ;
Pryor, HI ;
Sautter, TE ;
Gnade, BT ;
Thakar, JH ;
Knudson, GB .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (06) :559-562
[3]  
Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P889
[4]   In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne [J].
Choe, CH ;
Bouhaouala, SS ;
Brook, I ;
Elliott, TB ;
Knudson, GB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1766-1766
[5]   ANTIMICROBIAL SUSCEPTIBILITY OF BACILLUS-ANTHRACIS [J].
DOGANAY, M ;
AYDIN, N .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (03) :333-335
[6]   POSTEXPOSURE PROPHYLAXIS AGAINST EXPERIMENTAL INHALATION ANTHRAX [J].
FRIEDLANDER, AM ;
WELKOS, SL ;
PITT, MLM ;
EZZELL, JW ;
WORSHAM, PL ;
ROSE, KJ ;
IVINS, BE ;
LOWE, JR ;
HOWE, GB ;
MIKESELL, P ;
LAWRENCE, WB .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) :1239-1243
[7]   Anthrax as a biological weapon - Medical and public health management [J].
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Friedlander, AM ;
Hauer, J ;
McDade, J ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (18) :1735-1745
[8]  
Lightfoot N.F., 1990, Salisbury Med. Bull, V68, P95
[9]   Antimicrobial susceptibility testing of Bacillus anthracis:: Comparison of results obtained by using National Committee for Clinical Laboratory Standards broth microdilution reference and etest agar gradient diffusion methods [J].
Mohammed, MJ ;
Marston, CK ;
Popovic, T ;
Weyant, RS ;
Tenover, FC .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (06) :1902-1907
[10]  
National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS